Procyrion, Inc. is a medical device company focused on developing the world's first catheter-deployed heart pump, known as the Aortix system. This innovative technology is designed to assist heart function and improve clinical outcomes for patients with heart failure.

Procyrion

Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system.

Aortix™ is currently in the research and development phase and is not available for sale in any country.
(Caution: investigational device. Limited by federal law to investigational use.)

Scientific Health Development Partners

Aquinas

Jefferson River Capital

BlueBird Merchant Ventures

Fannin Innovation Studio

Houston Angel Network

Procyrion, Inc.

Our DRAIN-HF trial evaluating the #Aortix pump for acute decompensated #heartfailure patients is well underway. Congrats to Henry Ford Hospital and John Muir Hospital for enrolling multiple patients in this important study! 

#clinicaltrials #cardiorenalsyndrome #diureticresistance #innovation

Another DRAIN-HF site begins patient enrollment! Congrats to Dr. Miguel Alvarez Villela and the Northwell Health Lenox Hill team on enrolling your first patient in this groundbreaking trial for #heartfailure patients. 
 
#clinicaltrials #cardiorenalsyndrome #diureticresistance #Aortix #innovation

BREAKING NEWS: We are proud to be recognized as a #Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix technology and the potential it has to change the way patients with acute decompensated #heartfailure and cardiorenal syndrome are treated.

https://lnkd.in/gR47YYhU

First DRAIN-HF enrollment in the Bay Area! Congrats to Dr. Andrew Dublin, Dr. Wayland Lim and the team at John Muir Health on enrolling your first patient in this groundbreaking trial of Aortix for #heartfailure patients.  
#clinicaltrials #cardiorenalsyndrome #diureticresistance

Our President & CEO Eric Fain had the opportunity to connect with Tom Salemi, host of the DeviceTalks podcast, earlier this week. Eric details how our recent $57.7 million round will help us in our quest to make the company's innovative Aortix technology available to physicians and patients with acute decompensated heart failure and cardiorenal syndrome. 
https://bit.ly/3SvX7HD

COM:PROCYRION

Procyrion

Financials Not Available